• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大肠杆菌不耐热肠毒素的佐剂活性及其对小鼠口服耐受无关蛋白抗原诱导的影响。

Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

作者信息

Clements J D, Hartzog N M, Lyon F L

机构信息

Department of Microbiology and Immunology, Tulane University Medical Center, New Orleans, Louisiana.

出版信息

Vaccine. 1988 Jun;6(3):269-77. doi: 10.1016/0264-410x(88)90223-x.

DOI:10.1016/0264-410x(88)90223-x
PMID:3048010
Abstract

The ability of Escherichia coli heat-labile enterotoxin (LT) to influence the induction and maintenance of tolerance was examined in animals primed orally with a soluble protein antigen, ovalbumin (OVA), or in animals primed orally with two unrelated protein antigens administered simultaneously, OVA and bovine serum albumin (BSA). LT is immunologically and structurally related to the cholera enterotoxin (CT), which has been shown to be capable of abrogating oral tolerance to protein antigens when delivered simultaneously with the antigens. In this study, simultaneous administration of LT with OVA was shown to prevent the induction of tolerance to OVA and to increase the serum anti-OVA IgG response 30- to 90-fold over OVA-primed and PBS-primed animals, respectively. This effect was determined to be a function of the enzymatically active A subunit of the toxin since the B (binding) subunit alone was unable to influence tolerance induction. Animals fed LT with OVA after the initial OVA prime developed a significantly lower serum IgG and mucosal IgA anti-OVA response than those fed LT with OVA in the initial immunization, indicating that prior exposure to the antigen reduces the effectiveness of LT to influence tolerance and its ability to act as an adjuvant. LT was not able to abrogate tolerance once it had been established. Serum IgG and mucosal IgA responses in animals receiving LT on only a single occasion, that being upon first exposure to antigen, were equivalent to responses after three OVA/LT primes, indicating that commitment to responsiveness occurs early and upon first exposure to antigen.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在经口用可溶性蛋白抗原卵清蛋白(OVA)致敏的动物,或经口同时给予两种不相关蛋白抗原(OVA和牛血清白蛋白(BSA))致敏的动物中,检测了大肠杆菌不耐热肠毒素(LT)影响耐受性诱导和维持的能力。LT在免疫和结构上与霍乱肠毒素(CT)相关,已证明当与抗原同时递送时,CT能够消除对蛋白抗原的口服耐受性。在本研究中,OVA与LT同时给药可阻止对OVA耐受性的诱导,并使血清抗OVA IgG反应分别比OVA致敏和PBS致敏的动物增加30至90倍。该作用被确定为毒素酶活性A亚基的功能,因为单独的B(结合)亚基无法影响耐受性诱导。在初次用OVA致敏后给动物喂食OVA与LT,其血清IgG和粘膜IgA抗OVA反应明显低于初次免疫时喂食OVA与LT的动物,这表明预先接触抗原会降低LT影响耐受性的有效性及其作为佐剂的能力。一旦建立耐受性,LT就无法消除它。仅在首次接触抗原时单次接受LT的动物的血清IgG和粘膜IgA反应与三次OVA/LT致敏后的反应相当,这表明对反应性的承诺在首次接触抗原时就早早发生了。(摘要截短至250字)

相似文献

1
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.大肠杆菌不耐热肠毒素的佐剂活性及其对小鼠口服耐受无关蛋白抗原诱导的影响。
Vaccine. 1988 Jun;6(3):269-77. doi: 10.1016/0264-410x(88)90223-x.
2
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.大肠杆菌热不稳定肠毒素佐剂活性与ADP-核糖基转移酶活性的解离。
Infect Immun. 1995 May;63(5):1617-23. doi: 10.1128/iai.63.5.1617-1623.1995.
3
Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat-labile enterotoxin.
Pediatr Res. 1996 Apr;39(4 Pt 1):625-9. doi: 10.1203/00006450-199604000-00011.
4
Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.重组大肠杆菌不耐热肠毒素及其B亚基的黏膜免疫佐剂活性:通过用流感病毒表面抗原经鼻免疫诱导小鼠产生全身性IgG和分泌性IgA应答
Vaccine. 1998 Dec;16(20):2069-76. doi: 10.1016/s0264-410x(98)00076-0.
5
An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.霍乱样肠毒素诱导口服耐受产生长期阻断作用需要具有酶活性的A亚基:一种筛选黏膜佐剂的新方法。
Infect Immun. 2003 Dec;71(12):6850-6. doi: 10.1128/IAI.71.12.6850-6856.2003.
6
Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.用大肠杆菌不耐热肠毒素在裸皮肤上进行免疫接种可增强对共同给药的蛋白质和肽抗原的免疫反应,并保护小鼠免受致死性毒素攻击。
Immunology. 2001 Mar;102(3):344-51. doi: 10.1046/j.1365-2567.2001.01183.x.
7
MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.基于肠毒素的黏膜佐剂诱导的MHC I类限制性细胞毒性淋巴细胞反应。
J Immunol. 1999 Dec 15;163(12):6502-10.
8
Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.具有改变的神经节苷脂结合活性和降低的毒性的II型不耐热肠毒素LT-IIa突变体是有效的粘膜佐剂。
Infect Immun. 2007 Feb;75(2):621-33. doi: 10.1128/IAI.01009-06. Epub 2006 Nov 21.
9
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.使用CpG DNA和/或大肠杆菌不耐热肠毒素突变体作为佐剂对小鼠进行黏膜免疫。
Vaccine. 2001 Jun 14;19(27):3759-68. doi: 10.1016/s0264-410x(01)00088-3.
10
Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.大肠杆菌不耐热肠毒素重组A亚基的黏膜免疫原性及佐剂活性
Immunology. 1999 Aug;97(4):706-13. doi: 10.1046/j.1365-2567.1999.00817.x.

引用本文的文献

1
Protective antibodies against enterotoxigenic Escherichia coli are generated from heat-labile toxoid vaccination and exhibit subject- and vaccine-specific diversity.针对产肠毒素大肠杆菌的保护性抗体由不耐热类毒素疫苗接种产生,并表现出个体和疫苗特异性的多样性。
Med Microbiol Immunol. 2025 Feb 11;214(1):10. doi: 10.1007/s00430-025-00817-3.
2
Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study.经鼻给予脱毒 LTh(αK) 在轻至中度 COVID-19 患者中的安全性、耐受性和疗效:一项随机、双盲、安慰剂对照的 2 期研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2432105. doi: 10.1080/21645515.2024.2432105. Epub 2024 Nov 29.
3
Metabolic fitness of IgA plasma cells in the gut requires DOCK8.肠道中 IgA 浆细胞的代谢适应性需要 DOCK8。
Mucosal Immunol. 2024 Jun;17(3):431-449. doi: 10.1016/j.mucimm.2023.12.001. Epub 2023 Dec 28.
4
How Long Will It Take to Launch an Effective Vaccine for Humans?研发出一款对人类有效的疫苗需要多长时间?
Infect Drug Resist. 2023 Jun 15;16:3787-3805. doi: 10.2147/IDR.S412361. eCollection 2023.
5
Multiepitope Fusion Antigen: MEFA, an Epitope- and Structure-Based Vaccinology Platform for Multivalent Vaccine Development.多表位融合抗原:MEFA,一种基于表位和结构的疫苗学平台,用于多价疫苗的开发。
Methods Mol Biol. 2022;2414:151-169. doi: 10.1007/978-1-0716-1900-1_10.
6
Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems.颊黏膜和舌下疫苗:口腔黏膜免疫与递送系统综述
Vaccines (Basel). 2021 Oct 14;9(10):1177. doi: 10.3390/vaccines9101177.
7
Importance of Cry Proteins in Biotechnology: Initially a Bioinsecticide, Now a Vaccine Adjuvant.冷冻蛋白在生物技术中的重要性:最初是一种生物杀虫剂,现在是一种疫苗佐剂。
Life (Basel). 2021 Sep 23;11(10):999. doi: 10.3390/life11100999.
8
Advances in Oral Subunit Vaccine Design.口服亚单位疫苗设计的进展
Vaccines (Basel). 2020 Dec 22;9(1):1. doi: 10.3390/vaccines9010001.
9
Various Adjuvants Effect on Immunogenicity of Puumala Virus Vaccine.各种佐剂对普马拉病毒疫苗免疫原性的影响。
Front Cell Infect Microbiol. 2020 Oct 26;10:545371. doi: 10.3389/fcimb.2020.545371. eCollection 2020.
10
Chemically Synthesized Lipid A Shows a Potent and Safe Nasal Vaccine Adjuvant Activity for the Induction of -Specific IgA and Th17 Mediated Protective Immunity.化学合成的脂多糖A显示出一种强大且安全的鼻用疫苗佐剂活性,可诱导特异性IgA和Th17介导的保护性免疫。
Microorganisms. 2020 Jul 23;8(8):1102. doi: 10.3390/microorganisms8081102.